Informing PrEP Scale-up, Cost and Delivery in Mexico
Drugs, personnel, and laboratory costs comprised 50%, 38%, and 12% of program costs.
Can We Provide Tailored Care for Homeless HIV Patients?
A discussion as to why people with unstable housing living with HIV may not prefer telehealth versus consistent in-person care.
Shifting COVID-19 Concerns in the HIV Community
The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.
Once-Monthly PrEP May Become a Viable HIV Option
Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?
Increasing Family Physician Engagement with PrEP Therapy
Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.
Evaluating Adherence of PrEP Therapies
Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.
How Does Adherence of Daily Dosing vs Event-Driven PrEP Regimens Compare?
Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.
Resilience in People Living With HIV During the COVID-19 Pandemic
Impaired resilience was found to be associated with loneliness.
Providing Online HIV Services During the COVID-19 Pandemic
Virtual support services were crucial for providing continued care and education.
Screening for Potential PrEP Users at Retail Pharmacies
In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.
Islatravir Safe, Tolerable for HIV-1 PrEP in Phase 2A Trial
New 24-week findings from Merck highlight the potential of a 1-month PrEP option for low-risk patients.
PrEP Use Low Among Individuals With Self-Reported HIV Risk Factors
Many respondents reported having a lack of information about the use of PrEP.
Those With HIV Have High Rates of COVID-19 Hospitalizations, Mortality
PLWH should strictly maintain ART therapy and COVID-19 mitigation efforts.
Promoting HIV Partner Notification Services Using a People-Centered Approach
Crowdsourcing and other approaches may develop more effective interventions to promote PS.
Exploring PrEP Implementation Factors in the Southern US
More tailored strategies could improve PrEP provision in family planning clinics.
Majority of PrEP Users Do Not Maintain Adherence
A meta-analysis study found that 70% of PrEP users either stopped or had inadequate adherence within 6 months of initiation.
The COVID-19 Pandemic and Resumption of PrEP Therapy
Small survey from gay and bisexual men (GBM) inquired about their experiences during COVID-19 restrictions, and feedback on PrEP.
Impact of Home-Based Testing on Uptake and Knowledge of HIV Status
No significant difference was observed across the 3 study groups.
COVID-19 Humoral and T-Cell Immune Responses Among People Living With HIV
A positive relationship may exist between infection severity and adaptive immunity.
Outreach for PrEP Counseling Shows Ability to Reach Underserved Communities
In Brazil, a concerted effort of recruiting adolescents was made to go out and talk with them about PrEP.
Do Adverse Childhood Experiences Impact PrEP Uptake in Young Adulthood?
Rates of testing for HIV, as well as PrEP uptake, remain suboptimal in MSM of color.
Understanding PrEP Preferences in a Select Population
Investigators surveyed men who have sex with men (MSM) about long-acting injectable pre-exposure prophylaxis (PrEP) including attitudes towards potentially taking it and barriers to usage.
HIV Testing, Positive Results Dropped in the US During COVID-19
The pandemic's effect on in-person care prioritization may have indirectly influenced the rate of screening opportunities in at-risk persons.
Cabotegravir Plus Rilpivirine Well-Received by HIV Care Staff, Patients at 12 Months
New findings from CUSTOMIZE suggest the once-monthly injection therapy was feasibly implemented and generally favored to once-daily tablets.
Study: Homeless Persons with HIV Prefer Flexible Care Models, No Telehealth
Perspective gained from persons treated a real-world clinic may help better inform strategies to treat an HIV population that often struggles with viral suppression and consistent care.
COVID-19 Severe Risks Not Significant in People with HIV
A new study from IAS 2021 suggests persons with HIV hospitalized for COVID-19 do not face worse mortality nor major cardiovascular event risk.
Outreach Can Provide Needed Boost to Begin, Continue ART
Initiating and adhering to ART is a difficult task for a significant number of people living with HIV. A new study shows that making a concerted effort to find and encourage this population to get the care they need is not an impossible dream.
Dual Therapy MK-8591 Plus Doravirine Efficacious in Treatment-Naive PLWH
The percentage of participants who achieved HIV-1 RNA< 50 copies/mL in the 0.25 mg, 0.75 mg, 2.25 mg MK-8591 dose groups was 89.7%, 90.0%, and 77.4%, respectively, at week 48.
ADVANCE: 48-Week Data Support Dolutegravir-Containing ART Regimens
At week 48, 83.8% of participants in the TAF/FTC/DTG arm had HIV RNA < 50 copies/mL, 84.9% for TDF/FTC/DTG and 78.6% for TDF/FTC/EFV.
Week 96 GEMINI Results Reinforce Efficacy of DTG/3TC
GEMINI 1 & 2 are phase 3, randomized, double-blind, multicenter studies evaluating the 2-drug regimen of DTG/3TC in comparison with the 3-drug regimen of DTG + TDF/FTC.
2 Clarke Drive Cranbury, NJ 08512